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ABSTRACT 
Vitronectin is a multifunctional glycoprotein found in human serum as well as in 
the extracellular matrix (ECM). Vitronectin is found in circulation as a monomer, both as 
a double-chain form and a single-chain form, which results from proteolytic cleavage at 
the carboxy-terminal (C-terminal) position 379. Tissue and matrix associated vitronectin, 
however, is multimeric. Human vitronectin interacts with a variety of ligands implicated 
in controlling a number of physiological processes. These biological targets include 
heparin, plasminogen activator inhibitor-I (P AI-I), proteases such as thrombin and 
urokinase-type plasminogen activator (uP A) , serine protease inhibitor-protease 
complexes, the uP A receptor (uP AR), and a sub-class of cell-surface integrin receptors. 
Based on investigations into vitronectin-ligand structure/function relationships 
and threading methods, a computational model of vitronectin' s three-dimensional 
structure was designed organizing vitronectin into several domains including an amino-
terminal (N-terminal) somatomedin-B domain, a central hemopexin homology domain, 
and a C-terminal heparin binding domain. Although our structural model is a compelling 
foundation to understanding its ligand-binding interactions, we remain cautious and seek 
to confirm vitronectin's structure empirically. 
The purpose of this study is to use techniques in x-ray crystallography to elucidate 
the three-dimensional structure of full-length, native, monomeric vitronectin and 
ultimately determine the specifics of the various ligand-binding interactions that confer 
vitronectin with its dynamic functions. In addition, preliminary work towards a novel 
recombinant expression system using baby hamster kidney (BHK) cells has been 
performed using several techniques of molecular biology. 
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Chapter 1 
VITRONECTIN STRUCTURE AND FUNCTION: AN OVERVIEW 
Introduction 
Vitronectin was discovered in 1967 and was identified as a serum spreading factor 
with a cell-to-cell adhesive role (Holmes, et. al., 1967). Human vitronectin interacts with 
a variety of ligands implicated in controlling a number of physiological processes 
including coagulation, fibrinolysis, tumor metastasis, cellular migration, and the humoral 
immune response (Preissner, et. al., 1991a and 1991b). These macromolecular targets 
include heparin, plasminogen activator inhibitor-1 (P AI-I), proteases such as thrombin 
and urokinase-type plasminogen activator (uP A), serine protease inhibitor-protease 
complexes, the uP A receptor (uP AR), and a sub-class of cell-surface integrin receptors. 
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Although found in circulation and the ECM, vitronectin is synthesized in the liver 
and expressed at low levels in the lungs, kidneys, skin, and brain (Seiffert, et. al., 1991a 
and 1991 b). Vitronectin is present in vivo in two conformationally different forms. 
Circulating vitronectin is primarily in monomeric form at a concentration of 200-400 
Jlg/ml; tissue and matrix vitronectin are found mainly as a multimer (Preissner, et. al., 
1985, Barnes, et. al., 1983). 
Numerous functions have been ascribed to vitronectin, although the specifics of 
its structure have yet to be determined on the atomic level for several reasons: (l) its 
large size and conformational lability; (2) the lack of an adequate expression system has 
hindered the use of site-directed mutagenic studies; (3) purification of vitronectin from 
human serum yields both single-chain and double-chain forms, which cannot be 
adequately separated; 4) extensive post-translational modification leads to a high degree 
of sample heterogeneity. One characteristic of vitronectin that has indeed been harnessed 
for the purposes of research is its high propensity to adhere to surfaces. This adherence 
property has proved very useful for solid phase structure/function research. 
Localization and Tissue Distribution of Vitronectin 
In circulation, vitronectin has been found in complexes with PAI-1 (Derklerck, et. 
al., 1988, Mimuro, et. al., 1989, Wiman, et. al., 1988), the terminal complement C5b7 
complex (Podack et. al., 1977), and with the thrombin-antithrombin complex (TAT) (Ill, 
et. al., 1985). Vitronectin has also been found within platelet extracts and is released 
from platelet a granules upon thrombin stimulation (Parker, et. al., 1989, Preissner, et. 
al., 1989). Using immunohistochemical staining, it has been demonstrated that 
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vitronectin is present in loose connective tissues of skeletal muscle, lung, kidney, and 
skin (Hayman, et al., 1983). More recently, it has also been found located in the 
mineralized bone matrix (Seiffert 1996). There is also an age-dependent accumulation of 
vitronectin within dermal fibers (Dah1back, et al., 1993). Vitronectin most likely 
localizes to these tissues from circulation. 
Vitronectin mRNA is, however, found predominantly in hepatocytes, and most 
vitronectin is produced within the liver (Seiffert, et. al., 1991 a). Vitronectin expression 
in hepatocytes has been shown to be up-regulated by administering endotoxin (Seiffert, 
et. al., 1994); From these studies, there is evidence that the acute inflammatory response 
may regulate the synthesis of vitronectin. 
A vitronectin knockout mouse has been generated uSIng gene displacement 
(Zheng, et. al., 1995). No vitronectin was found in the serum of the knockout (-/-) mice. 
Studies performed thus far on these knockout mice have shown that vitronectin 
deficiency has no observable effect on development, survival, or fertility. Recently 
however, several studies on the vitronectin-deficient mice describe an important 
regulatory role for vitronectin in thrombogenesis. In one study, an anti thrombotic effect 
of vitronectin was identified at sites of platelet-rich thrombi (Fay, et al., 1999), with the 
vitronectin knockout forming thrombi faster than the wild-type mouse. Additionally, in 
another vascular linjury model of occlusive thrombus formation, the absence of 
vitronectin inhibited reocclusion and thus modulated fibrinolysis (Eitzman, et al., 2000). 
Arterial thrombi in vitronectin-deficient mice are unstable and frequently embo1ize 
(Konstantinides, et al., 2001). 
3 
Vitronectin is localized to damaged tissue in different pathological conditions: (l) 
modified vitronectin characterized by advanced glycosylation and a reduced binding 
affinity for P AI-I, heparin, and cell surface integrin receptors is found localized in the 
ECM and vasculature of retinae in diabetic rats (Hammes, et. al., 1996); (2) anti-
vitronectin monoclonal antibodies react with atheroslecrotic lesion proteins (Sato, et. al., 
1990) and rheumatoid arthritic synovia proteins (Rosenblum, et. al., 1996); (3) although 
not detected in healthy brain tissue, vitronectin immunoreactivity co-localizes with 
neurofibrillary tangles in the brain of Alzheimer's patients (Akiyama, et. al., 1991, 
Gladson, et. al., 1991); (4) vitronectin is detected in numerous inflamed and necrotic 
tissues including the cirrhotic liver (Inuzuka, et. al., 1992), cancerous breast tissue 
(Niculesca, et. al., 1992), and in areas of acute myocardial infarction (Rus, et. al., 1987). 
Target ligands for vitronectin include components of the ECM, cell-surface 
integrin receptors, participants of the fibrinolytic and coagulatory pathways, and 
complement factors. Together with the information concerning vitronectin's tissue 
distribution, these macromolecular targets suggest an important role for vitronectin in 
wound healing and repair, tissue remodeling, angiogenesis, and tumor metastasis. 
Vitronectin Function 
As previously mentioned, vitronectin IS an important regulatory protein 
implicated in the control of coagulation, inflammation, and wound healing. The events 
leading to thrombus formation constitute the dynamic coagulation pathway. When an 
insult damages a blood vessel wall, a proteolytic cascade induces cleavage of the inactive 
zymogen prothrombin into its active form, thrombin. The crystal structure of a thrombin 
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and antithrombin III is shown in figure 1-1. Thrombin belongs to the serine protease 
enzyme family, and once activated, it initiates the formation of a thrombus by cleaving 
another protein, fibrinogen. The products of the fibrinogen cleavage reaction are 
insoluble fibrin molecules that aggregate to form the proteinacious meshwork of the 
thrombus. Thrombin is subsequently inactivated by the serine Qrotease inhibitor (serpin) 
antithrombin, which binds thrombin in its active site forming an inactive protease 
inhibitor complex (Rosenberg, et. al., 1973). Proteoglycans, such as heparin, present at 
blood vessel wall surfaces accelerate the otherwise slow inhibitory activity of 
antithrombin. The mechanism by which antithrombin activity is accelerated occurs by 
antithrombin binding the specific pentasaccharide sequence of heparin, inducing a 
conformational change in antithrombin that enhances the rate at which antithrombin 
binds thrombin (Olson, et. al., 1981). Moreover, heparin serves as a scaffold on which 
thrombin and antithrombin interaction can take place, allowing increased local 
concentrations of both proteins (Peterson, et. al., 1987). Such functions of heparin 
explain its ability to serve as an anti-coagulant frequently utilized in clinical medicine 
(Patrick, et al., 1991). 
The heparin-vitronectin complex formation has a binding constant in the 
micromolar range (Zhuang, et. al., 1997). Vitronectin neutralizes the anti-coagulant 
activity of heparin by competing with both thrombin and antithrombin for heparin 
binding (Preissner, et. al., 1987). Vitronectin also binds to the inactive TAT (Ill, et. al., 
1985). Once vitronectin binds TAT, the inactive complex is hastily cleared from 
circulation (de Boer, et. al., 1993, Shifman, et. al., 1982). 
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Figure 1-1: The crystal structure of a thrombin (A) and antithrombin III (B). a 
thrombin is composed of a 6 kD "A" chain, which is covalently linked to a 31 kD 
"B" chain through a single disulfide bond. Antithrombin ill contains three intra-
chain disulfide bonds, a carbohydrate rich domain, an N-terminal heparin binding 
domain, and a C-terminal serine protease binding domain. The mechanism of TAT · 
complex formation involves the formation of a stable 1: 1 complex between the 
active site of thrombin and the scissile bond (R 385-S 386) of antithrombin ill. The 
active serine of thrombin has been shown to form a covalent intermediate with the PI 
amino acid (R 385) of antithrombin ill (Rosenberg, et. ai., 1973). 
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After an injury, the complement cascade is initiated to prevent infiltration of 
foreign bacteria. Via proteolytic modification, complement factor C5 is activated to C5b 
(Muller-Eberhard, et. al., 1986). C5b subsequently reacts with two additional 
complement proteins, C6 and C7 respectively. The C7 binding event renders the 
complex amphipathic, allowing it to insert itself within the membrane. Alternatively, the 
C5b-7 complex can react with C8 forming the C5b-8 complex responsible for catalyzing 
polymerization of complement factor C9, in tum generating a membrane-penetrating 
tubule with cytolytic activity (Tschopp, et. al., 1985). Vitronectin is capable of limiting 
the lysis of neighboring cells by inhibiting the cytolytic activity of the membrane attack 
complex (MAC). Vitronectin binds a hydrophobic site on the C5b-7 complex, preventing 
its insertion into the plasma membrane (Podack, et. al., 1978). Vitronectin also protects 
against cytotoxic T cell-mediated cell lysis through inhibition of the perforin 
polymerization (Tschopp, et. al., 1985). 
At the thrombus, platelets are induced to release proteases by thrombin 
stimulation, and these proteases commence the wound healing/repair process. This 
proteolytic enzyme increase is involved in fibrinolysis. Plasminogen activators cleave 
plasminogen to its active form, plasmin, which subsequently degrades the fibrin 
meshwork of the clot. P AI-1 is responsible for the inactivation of plasminogen 
activators, which limits the generation of plasmin (Heckman, et. al., 1988). Like 
antithrombin, P AI-1 is a serpin, and it binds the active sites of plasminogen activators by 
forming an inactive protease-inhibitor complex (Huber, et. al., 1989). It has been 
determined from many structure/function studies and from x-ray crystallographic work 
that PAI-1 exists in two conformationally different forms, an active form and a latent 
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form (Fig. 1-2) (Sharp, et. al., 1999, Mottonen, et. al., 1992, Nar, et. al., 2000). The 
active-to-latent transition of PAI-l involves incorporation of a surface-exposed loop 
containing the reactive center into the central ~-sheet of the protein. Using site-directed 
mutagenesis (Lawrence, et. al., 1994), monoclonal antibodies (van Meijer, et. aI., 1994, 
Wind, et. al., 2001), and a combination of peptide mapping and recombinant protein 
fusions (Padmanabhan, et. al., 1995), a vitronectin-binding site on P AI-1 has been 
localized to residues that lie within the central ~-sheet and adjacent secondary structures. 
Apparently, vitronectin contacts residues in the vicinity of the central ~-sheet of PAI-1, 
thus constraining movement of the strands that is necessary for incorporation of the 
reactive loop into the central ~-sheet (Lawrence, et. al., 1994, Wind, et. al., 2001). 
Because vitronectin binds PAl-I, an anti-fibrinolytic protein, and stabilizes its active 
conformation, it functions as a negative fibrinolytic regulator. Vitronectin binds collagen 
and is an integral part of the ECM (Gebb, et. al., 1886). After an insult, multimeric, 
matrix vitronectin may localize PAI-1 and plasminogen to the injury site in order to 
regulate proteolytic events requisite for tissue remodeling. 
Matrix vitronectin is also a key component in cell-migration and attachment. 
Vitronectin is capable of binding two classes of cell-surface receptors. It binds the 
integrin receptor family at its arginine-glycine-aspartic acid (RGD) integrin epitope 
sequence (Suzuki, et. al., 1984). Table I-I illustrates the distribution, function, and 
specificities of vitronectin-binding integrins. Integrins are heterodimeric proteins 
that recognize the RGD sequence in several adhesive proteins such as fibronectin, 
fibrinogen, and von Willebrand Factor (Pierschbacher, et. al., 1987, Ruoslahti, et. al., 
1987). Each integrin recognizes specific binding targets, and this ligand specificity is 
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Figure 1-2 Structure of Active (A) and Latent (B) PAl-I: 
The 3D structure of the active fonn of PAI-I (A) illustrates features pertinent to the inhibitory 
mechanism of proteases by serpins. Serpins are folded around a large, central ~-sheet (the A sheet) 
from which protrudes a surface-exposed loop (the reactive-center loop or RCL). Within this loop 
region are the residues recognized as substrates by the target protease (uPA or tPA), with the reactive 
center peptide bond denoted PI-PI'. Upon attack of the protease, this PI-PI' peptide bond of PAI-I is 
cleaved by nucleophilic attack of the active-site serine, and an acyl-intennediate is fonned. In contrast 
to the normal progression of proteolysis, this acyl-intennediate is extremely long-lived due to a 
negligible rate of deacylation. Structural rearrangements occur so that the two ends of the cleaved loop 
separate, and the PI end, with the enzyme covalently coupled, is partially inserted into the central p-
sheet. As such, the protease is inactivated by formation of a 1: 1 stable, covalent complex with the 
serpin. PAI-I is unique among the serpins because it readily relaxes from this active fonn (A) to a 
latent, inactive fonn (B). As shown, this occurs by insertion of the RCL into the central p-sheet to 
contribute a sixth strand to this secondary structural element. This refolding is thennodynamically 
driven, since the latent fonn of PAl -1 is more stable. 
9 
Table 1-1: Distribution, Function, and Specificities of Vitronectin-Binding Integrins. 
Integrin Ligands Cell-Type Functions 
alIb~3 Fibrinogen Platelets Platelet adhesion to the vessel wall 
(IIbIIIJ Fibronectin 
von Willebrand Factor 
Vitronectin 
aV~3 Bone Sialoprotein Osteoclasts Osteoporosis, bone resoption 
Vitronectin Osteosarcoma 
Fibrinogen Endothelial Cells Angiogenesis 
Fibronectin Smooth Muscle Cells Cell differentiation 
Perlecan Fibroblasts Diabetic retinopathy 
Thrombospondin Leukocytes 
von Willebrand Factor (others) 
Vitronectin 
Macrophages Phagocytosis of apoptotic cells 
Me .t 
_s Proplatet fonnation 
Mouse Ooctyes Fertilization? Pre-implantation development? 
Melanoma Cells Tumor progression and invasion 
Glioblastoma Cells 
avJ35 Vitronectin Fibroblasts Vitronectinendocytosis 
Keratinocytes Cell adhesion on vitronectin matrix 
Pancreatic Carcinoma 
Lung Carinoma 
a.V~1 Vitronectin Fibroblasts 
Fibronectin Tumor Cell Lines 
Mouse Ooctyes Fertilization? Pre-implantation development? 
...... 
o 
governed by the particular a and ~ subunits of which it is made. Four vitronectin-
binding integrins have been identified including aIIb~3, av~3, av~5, and av~l cell-surface 
receptors (Germer, et. at., 1998). aIIb~3 integrin is expressed on platelet surfaces and 
binds vitronectin, thereby facilitating the adhesion of platelets to the vasculature sub-
endothelium during thrombus formation (Thiagarajan, et. at., 1988). Within serum, 
vitronectin functions as the primary cell-spreading factor via its interactions with integrin 
a vP3, which has come to be known as the "vitronectin receptor" (Pytela, et at., 1985 and 
Horton, et at., 1997). This vitronectin-integrin interaction signals integrin 
phosphorylation and subsequently endothelial cell differentiation (Bhattacharya, et at., 
1995). The avps receptor mediates endocytosis of ECM-vitronectin by fibroblasts. In 
fact, vitronectin is the only ligand known for av~s (Panetti, et at., 1993). 
Vitronectin binds the urokinase plasminogen activator receptors (uP AR) on 
monocytes, endothelial cells, and myeloid cells. Bindirtg uP AR promotes the adhesion of 
these cells to the ECM. Cell migration and ECM degradation Jis facilitated by protease 
activity localized to the cell surface. This protease localization is promoted by the 
binding event between uP AR and urokinase type plasminogen activator (uP A) (Vassali, 
et at., 1985). uPAR is anchored in the membrane by a GPI moiety (Ploug, et at., 1991), 
thus intracellular signaling must be transduced via coupling to another receptor. Such 
coupled linking events are believed to be mediated by integrins. It has been shown that 
vitronectin binds uP AR at a site different from that of uP A. Moreover, it has been 
proposed that uP A might have a synergistic effect on the vitronectin binding event (Walt, 
et at., 1994 and Wei, et at., 1994). PAI-l and uPAR share a vitronectin binding site, and 
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P AI-1 competes with uP AR for vitronectin binding subsequently leading to cell 
detachment and migration (Waltz, et al., 1997; Kjoller, et al., 1997; Deng, et al., 1996). 
Structural Organization 
Multi-functional proteins are commonly found to be composed of independently 
folded domains arranged linearly with respect to amino acid sequence. This means of 
organization allocates ligand binding to different, independent epitopes. Vitronectin is 
thought to be such a multi-domain protein. 
The multi-domain hypothesis for vitronectin has been supported by proteolytic 
experiments, because liberated vitronectin fragments often retain their ligand binding 
function, a fact often indicative of a multi-domain arrangement. There are two sites in 
vitronectin that are quite accessible to proteolysis: 1) an N-terminal sequence within 
residues 44 and 90, and 2) a C-terminal site within residues 340-370. Plasmin (Chain, et 
al., 1991; Gechtman, et al., 1997), thrombin (Gechtman, et al., 1997), and mast-cell 
tryptase (Cynthia Peterson and David Johnson, unpublished observation) cleave 
vitronectin within residues 340-370. Prolonged digestion of vitronectin with plasmin and 
mass-cell tryptase results in N-terminal cleavage between K88 and G89 (Kost, et al., 
1996). Trypsin cleaves the R44 _G45 peptide bond (Sigurdardottir, et al., 1994). An 
illustrated list of plasmin/trypsin cleavage sites is depicted in figure 1-3. 
Synthetic peptides and monoclonal antibodies have also been useful in assigning 
functional domains to the vitronectin sequence. A number of synthetic peptides have 
been observed to either mimic vitronectin function or inhibit ligand binding. The binding 
functions of the various vitronectin peptides are shown in figure 1-4. The use of 
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Figure 1- 4 Binding Functions of Vitronectin Peptides. The synthetic and phage-derived peptides shown 
above hav~ LJeen assigned with binding affinities as described below. Liang et al. identified two polypeptides (III ) expressed on phage surface which bind heparin-sepharose (98). The synthetic RGDS peptide (~ ) 
inhibits vitronectin binding to cells which express integrin receptors (59, 63). Kost localized a plasminogen 
binding site in vitronectin using a synthetic peptide ( ~, which inhibited plasminogen binding to immobilized 
vitronectin (115). Liang et al. found that phage expressing several polypeptide sequences (.) bound to 
StreptococclIspyogenes and that a synthetic peptide inhibited binding of the bacteria to vitronectin and 
hemopexin (106, l07).A synthetic peptide at the C-terminal end of vitro nee tin ( 11111111) binds heparin (115), 
competes with immobilized vitronectin for binding PAl-l (115), inhibits complement mediated cell lysis by 
interacting with complement C5b7 (51) and or C9 (120) and mediates binding ofvitronectin to Pneumocyslis 
carinii (124). A synthetic peptide derived from a sequence close to the N-terrninus ofvitronectin spans residues 
111-124 (.). This peptide stabilizes PAI-] activity (99). Synthetic peptides corresponding to residues 362-380 
also display PAI-} binding activity (I ]5,119) _ ). 
monoclonal antibodies is based on the ability of some of them to compete with ligands 
for binding particular vitronectin epitopes. 
The Signal Sequence: Vitronectin is translated from mRNA assembled from 8 
exons (Jenne, et al., 1987). Exon one encodes the 19 amino acid hydrophobic signal 
sequence removed after vitronectin secretion from hepatocytes. The 7 remaining exons 
encode the mature, 459 amino acid protein. 
The Somatomedin B Domain: The N-terminal 42 amino acids are encoded by 
exon 2. Exon three encodes the two additional amino acids of the somatomedin B 
domain of vitronectin (Jenne, et aI., 1987). This domain was given its name due its 
sequence being identical to that of circulating somatomedin B, which is present in serum 
at concentrations of 12-14 /-lg/ml (Wachenberg, et al., 1980). Cleavage by an as of yet 
unidentified protease is believed to release the somatomedin B domain from vitronectin 
in vivo (Tomasini, et al., 1991), since a separate gene encoding somatomedin B has not 
been identified. The function of somatomedin B is unknown. Proteolysis of vitronectin 
by trypsin releases the somatomedin B domain in vitro (Sigurdardottir, et al., 1994). 
While the somatomedin B domain harbors numerous arginines and lysines, its sequence 
remains intact after prolonged protease digestion. This ability to resist cleavage offers 
evidence of a tightly folded domain free of protease accessible regions. In fact, eight of 
the 44 somatomedin B domain amino acids are cysteines, which form an intradomain 
disulfide "knot." This disulfide network is believed to facilitate the tightly folded nature 
of the domain structure. The cysteine rich sequence within vitronectin is homologous to 
hydrophobic cysteine-rich repeats of B-cell membrane glycoprotein PC-l (Buckley, et 
al., 1990), megakyrocyte-stimulating factor (Merberg, et al., 1993), and autotaxin 
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(Seiffert, et ai., 1991). These proteins, however, share no functional similarity to 
vitronectin or to the somatomedin B domain itself. 
Studies including proteolysis and epitope mapping support the localization of a 
P AI-1 binding site to the somatomedin B domain. It has been demonstrated that P AI-1 
could bind a 6-kD CNBr fragment derived from vitronectin's N-terminus, whereas 
heparin could not (Seiffert, et ai., 1991). The cleaved fragment competed against 
immobilized vitronectin for P AI-1, and only bound P AI-1 in its active conformation. 
Thrombin cleavage of vitronectin also yields a 38-kD N-terminal fragment that binds 
PAI-1 (Seiffert, et ai., 1991). After cleavage by trypsin, an N-terminal vitronectin 
fragment was found to bind and subsequently stabilize P AI-1 in its active form 
(Sigurdardottir, et ai., 1994).- In addition, a monoclonal antibody that recognizes a 
vitronectin N-terminal epitope, mAB 153, competed with P AI-1 for vitronectin binding 
and was capable of disrupting vitronectin-PAI-1 complexes (Seiffert, et ai., 1994). 
A uP AR binding site has also been localized to the somatomedin B domain of 
vitronectin. The recombinant somatomedin B domain polypeptide consisting of residues 
1-41 competes with immobilized vitronectin for binding the urokinase receptor, and a 
somatomedin B mutant incapable of binding P AI-1 was unable to bind uP AR (Deng, et 
ai., 1996). mAB 153, mentioned previously, prevents vitronectin from binding 
immobilized complexes containing uP AR, P AI-1, and plasminogen activator (Deng, et 
ai., 1996). 
Cell Binding Sequence: An arginine-glycine-aspartic acid (RGD) sequence 
flanks the somatomedin B domain. This RGD sequence is found to be conserved in a 
number of ECM proteins including fibronectin, fibrinogen, and von Willebrand Factor. It 
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has been demonstrated that synthetic peptides derived from the amIno acid sequence 
adj acent to the RGD sequence prevent integrin-bearing cell adhesion to vitronectin 
(Pierschbacher, et al., 1987; Hayman, et al., 1985). The RGD motif is the primary 
determinant in integrin-mediated cell binding, as determined by site-directed 
mutagenesis. Integrin-mediated cell binding activity can be demolished by conservative 
mutations of the RGD sequence including KGD, RAD, or RGE (Sane, et al., 1993; 
Cherny, et al., 1993). 
The Connecting Region: The integrin-binding region connects the somatomedin 
B domain to a stretch of cysteine-free amino acids (46-130) in vitronectin. It is within 
this "connecting region" that a number of post-translational modifications are made. 
Tyrosines 56 and 59 are modified by sulfation (Jenne, et al., 1989). An N-linked 
glycosylation site is found on asparagine-67 (Tomasini, et al., 1991). Vitronectin is a 
substrate for transglutaminase and factor XlIIa in vitro (Sane, et al., 1993). 
Transglutamination induces the formation of higher order vitronectin complexes resistant 
to dissociation by SDS and reducing agents. Glutamine residues 73, 84, 86, and 93 are 
believed to be the primary transaminoglutaminase substrates in transaminoglutaminate 
reactions due to their incorporation of putrescine after treatment (Skorstengaard, et al., 
1990). It has not been established whether transaminoglutaminase-mediated 
multimerization ofvitronectin occurs in vivo. 
The connecting region harbors binding sites for several ligands. Monoclonal 
antibodies with connecting regIon epitopes compete with collagen for binding 
immobilized vitronectin (Morris, et al., 1994). A polypeptide sequence from within the 
connecting region binds heparin and is capable of competing for immobilized vitronectin 
17 
for heparin binding, as shown by phage display (Liang, et at., 1997). An additional PAI-
l binding site has been localized to the connecting region by screening fragments 
produced from Staphylococcus V8 protease for the ability to bind and subsequently 
stabilize active P AI-1 (Mimuro, et at., 1993). A vitronectin fragment composed of 
residues 115-121 has been shown to compete with PAI-1 for binding to immobilized 
vitronectin. This fragment's ability to stabilize active PAI-1 has also been verified using 
kinetic assays. 
Hemopexin Repeats: Two additional homologous domains, residues 131-268 and 
269-549, comprise the remainder of the vitronectin sequence. Six cysteines reside within 
this N-terminal portion. Two of these cysteines are reduced and buried within the 
molecule's folded structure (Zhuang, et at., 1996). There are two additional N-linked 
glycosylation sites, asparagines 150 and 223 (Tomasini, et at., 1991). As is found to be 
characteristic of both the somatomedin B domain and the connecting region, the 
hemopexin repeats are highly resistant to proteolytic cleavage. The domains have been 
named for their homology to the symmetrical heme transport protein, hempopexin 
(Jenne, et at., 1987; Stanley, 1986). The individual domains of he mopex in are composed 
of 4 tandem repeats. The two domains are connected by a flexible hinge region holding 
the two domains within close proximity of each other. It is believed that upon binding 
heme, a conformational change is mediated within the protein, exposing liver cell 
receptor binding sites at the interface of the two domains (Smith, et aI., 1988). 
Hemopexin-like domains are found in matrix metalloproteinases (MMP) such as 
collagenase and gelatinase (Wallon, et aI., 1997). In these examples, the hemopexin 
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domains are believed to mediate binding to the ECM, heparin, and cells (Wall on et aI., 
1997; 103). 
Unlike hempopexin, vitronectin has not been found to bind heme, thus the 
function of the hemopexin tandem repeats of vitronectin has yet to be appreciated. One 
possibility is that these domains may facilitate binding bacteria. For example, it has been 
shown that vitronectin exhibits affinity for Escherichia coli and might facilitate their 
adherence to endothelial cells (Valentin-Weigand, et al., 1988). It has also been shown 
that mannose and various oligo saccharides are capable of inhibiting the binding of 
vitronectin to Staphylococcus aureus, and sialic acid-binding proteins can inhibit 
vitronectin binding to Helicobacter pylori. Such inhibitory data suggests an involvement 
of sugars in the recognition of bacterial surface proteins (Wadstrom, et al., 1993). 
Because the hemopexin repeats harbor two of vitronectin's three oligosaccharides, this 
domain may be a potential bacteria binding target. In fact, peptides from the hemopexin 
sequence have been shown to have affinity for Streptococcus pyogenes. The bacteria 
bind hemopexin as well as vitronectin, and the binding sequence identified was used to 
derive synthetic peptides which inhibited the ability of streptococci to bind both 
hemopexin and vitronectin. 
The Heparin Binding Sequence: The first hemopexin domain in the vitronectin 
sequence is complete in the sense that it contains all four tandem repeats found natively 
in the domains of hemopexin. The second hemopexin domain, however, contains only 
three hemopexin sequence repeats. Between the second and third tandem repeat of the 
second hemopexin domain lies a sequence, residues 345-379, of highly charged amino 
acids. This sequence region harbors two motifs of charged/uncharged amino acids that 
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corresponds to the heparin-binding consensus sequence derived from numerous heparin-
binding proteins (Cardin, et at., 1989; Sobel, et at., 1992). In addition, serine at position 
378 is phosphorylated in vivo, and it has been found that it can be phosphorylated in vitro 
by protein kinase A (McGuire, et at., 1988; Gechtman, et al., 1997; Korc-Grodzicki, et 
aI., 1998; Korc-Grodzicki, et at., 1990). As previously mentioned, vitronectin circulates 
in both a two chain form and a one chain form that results from proteolytic cleavage 
between arginine 379 and alanine 380 (Dahlback, et aI., 1985). Unlike the majority of 
the tightly folded vitronectin sequences, the charged heparin-binding sequence and the 
sequences flanking either side exhibit increased susceptibility to proteolytic cleavage in 
vitro. 
Support for assIgnIng heparin-binding activity to this site in vitronectin IS 
supported by the high degree of similarity it has with other known heparin-binding motifs 
in proteins such as thrombin, antithrombin, and glial-derived nexin. A number of 
experimental observations support the assignment as well : 1) a CNBr cleavage product 
containing the sequence exhibits affinity for heparin in ligand blotting assays, competes 
for full-length vitronectin for heparin binding, and neutralizes heparin anti-coagulant 
activity (Suzuki, et at., 1984); and 2) synthetic peptides and monoclonal antibodies with 
epitopes within this region prevent heparin from binding this sequence on vitronectin 
(Kost, et at., 1992); 3) plasmin proteolysis within this region has been found to hinder the 
heparin-binding activity of vitronectin (Gechtman, et at., 19 97; Kost, et at., 1996); and 4) 
removal of sequences 306-370 and 331-383 using thrombin and elastase disrupts the 
heparin-binding activity of vitronectin (Gechtman, et at., 1997). 
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The heparin binding site serves as a binding site for a number of additional 
vitronectin target ligands including an additional PAI-1 binding site (Chain, et al., 1991; 
Preissner, et aI., 1990; Sane, et aI., 1991; Gechtman, et al., 1993), plasminogen 
(Preissner, et al., 1990), the complement complex (Tschoppi, et al., 1985; Milis et al., 
1993), uPAR (Deng, et al., 1996), and collagen (Ishikawa-Sakurai, et al., 1993; Ishikawa 
et al., 1992). Evidence supporting uPAR and complement complex binding to the 
vitronectin heparin-binding sequence stems from studies performed in which a CNBr 
derived fragment containing the heparin-binding sequence or synthetic peptides derived 
from the heparin-binding sequence inhibits the binding of these ligands to full-length 
vitronectin. Localization of a PAI-1 and plasminogen binding sites are better empirically 
supported. 
Plasmin cleavage of vitronectin yields a fragment, residues 1-361, that retains the 
capability to bind plasminogen, suggesting that this cleaved fragment retains a high 
degree of its natively folded structure (Gechtman, et al., 1997; Kost, et al., 1992). The 
plasminogen epitope was localized to the C-terminus, for upon treatment of the fragment 
with carboxypeptidase, the plasminogen-binding activity is disrupted. Using overlapping 
synthetic peptides derived from the heparin binding site, the plasminogen binding site has 
been mapped to residues 340-348 (Kost, et al., 1992). Additionally, cathepsin D and 
Staphylococcus V8 protease generated vitronectin fragments have been shown to bind 
both heparin and plasminogen in ligand-blotting assays (Preissner, et al., 1990). 
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Functional Regulation 
There are discrepancies regarding the precise assignment of ligand binding sites 
to vitronectin, nonetheless, our lab follows the general acceptance that ligand binding 
sites are localized to linear epitopes, which fold into discrete domains. Such binding site 
organization is capable of accommodating multiple ligands, and it is possible that 
vitronectin can interact simultaneously with different ligands so as to facilitate a "cross-
talk" between separate physiological systems. Some examples found in literature that 
support this idea include: 1) vitronectin binds glycosaminoglycans concurrently with the 
TAT complex (de Boer, et at., 1992). The apparent affinity of vitronectin for 
glycosaminoglycans increases due to interactions during TAT binding (Patrick, et at., 
1991). The vitronectin-protease ternary complex is endocytosed by endothelial cells in a 
manner dependent on the glycosaminoglycan binding site of vitronectin. Such 
dependence suggests that both TAT and glycosaminoglycan binding functions are 
essential for vitronectin-mediated protein-inhibitor complex clearance from circulation. 
2) Vitronectin is incorporated into the ECM via interactions with collagen and heparin 
sulfate glycosaminoglycans (Ishikawa, et at., 1992; Sane, et at., 1990; Thiagarajan, et at., 
1996). ECM vitronectin binds uP AR and integrin receptors on cells. It also binds 
plasminogen and PAI-l (Preissner, et at., 1990; Mimuro, et at., 1987; Owensby et at., 
1991). Vitronectin functions as a biological adhesive by interacting with immobilized 
matrix molecules and cells/plasma molecules, and thus facilitates cellular adherence and 
localization of fibrinolytic proteins to the endothelium. 3) Vitronectin incorporated into 
the terminal complement complex stimulates tyrosine phosphorylation in fibroblast cells 
in an integrin-dependent manner (Bhattacharya, et at., 1995). The RGD and complement 
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sites on vitronectin function in tandem to convey extracellular inflammatory information 
to intracellular signal transduction pathways. Vitronectin's domain organization allows it 
to exhibit multiple functions. The expression of vitronectin function in vivo may also be 
regulated by the protein's oligomeric state, enzymatic modifications, and by its vascular 
localization. 
Conformational Lability: Vitronectin is conformationally labile and displays 
differential binding activities, which depend on the specificity of its fold. It was noted 
that urea-treated vitronectin was able to bind heparin-Sepharose with greater affinity than 
non-denatured vitronectin at physiological ionic strength (Barnes, et at., 1985; Hayashi, 
et at., 1985). This observation led to the speculation of an encrypted heparin-binding 
sequence in the native fold of the molecule (Hayashi, et at., 1985; Preissner, et at., 1987). 
For example, heat or pH could mimic the change in fold, resulting in a vitronectin 
conformer capable of binding heparin more efficiently in solid phase assays. Based on 
these observations as well as on the sequence homology with hemopexin, it was 
suggested by Preissner, et al. that the cationic heparin-binding sequence was non-
functional in native vitronectin due to acidic residue interactions near vitronectin's N-
terminus (Preissner, et at., 1987). According to this model, vitronectin adopts an "open" 
conformation following denaturation exposing the natively encrypted heparin-binding 
domain. This theory has been widely accepted, and virtually all empirical data is 
interpreted with the presupposition of an encrypted heparin-binding site. 
It has been demonstrated that the monoclonal antibody 8E6, which blocks heparin 
binding to vitronectin, preferentially recognizes the denatured/renatured form of 
vitronectin (Tomasini, et at., 1989; Tomasini, et at., 1988). With the contention that the 
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8E6 epitope was the heparin binding site, this data seemed to support Preissner's 
encrypted-binding site model. Figure 1-5 illustrates the encrypted heparin binding site 
model. Moreover, renatured vitronectin binds more avidly to P AI-I (Lawrence, et ai., 
1997) and collagen (Ishikawa, et ai., 1992) in solid phase assays. Additionally, a CNBr-
derived C-terminal fragment of vitronectin prevents complement-mediated cytolysis and 
inhibits heparin activity more effectively than intact vitronectin (Tschopp, et ai., 1988). 
According to the prevailing encrypted heparin binding site theory, liberating this 
fragment from the native fold of the molecule increases its accessibility and increases its 
activity. 
Importantly, evidence has recently been found that argues against the encrypted 
heparin binding site that other functional regions of vitronectin are buried in the native 
fold of the molecule and increase in activity after refolding. Dietmar Seiffert found that 
the 8E6 monoclonal antibody, which had been used extensively in support of the 
encrypted heparin binding site theory, mapped to a sequence within the first hemopexin 
repeat rather than to the heparin binding site (Seiffert, et ai., 1995). Furthermore, other 
monoclonal antibodies possessing epitopes outside of the heparin binding sequence 
preferentially recognize refolded vitronectin (Seiffert, et ai., 1991). Binding sites for 
ligands such as PAl -1 and collagen, which display higher affinity for refolded vitronectin, 
have also been mapped outside of the heparin-binding region of the protein. Integrins, 
which recognize the N-terminal RGD motif, bind more efficiently to refolded vitronectin 
(Seiffert, et ai., 1997). In accordance with the commonly accepted theory that vitronectin 
natively adopts a "closed" conformation, most believe that these monoclonal antibodies 
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Somatomedin B 
Somatomedin B 
Closed Conformation 
Heparin-Binding Site 
~'/ 
Hemopexin Domain I 
lUDrOlding 
Refolding 
Open Conformation 
Heparin-Binding Site 
Hemopexin Domain I 
Fig. 1.5: Encrypted Heparin Binding Site Model. The model suggested by Preissner 
et al suggests that plasma vitronectin exists in a "closes conformation" stabilized by salt 
bridges between the cationic heparin binding site and negatively charged sulfated amino 
acids in the Connecting region. After unfolding and refolding or treatment with certain 
ligands, the "hinge" region moves the two hemopexin domains apart, exposing the 
heparin binding site. 
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and ligands display enhanced affinity for renatured vitronectin because their binding sites 
have been exposed as a result of denaturation. 
In contrast, Dietmar Seiffert has posed a theory to explain the altered function of 
refolded vitronectin. Seiffert noted that native vitronectin indeed binds heparin (Seiffert, 
1997). Thus, his model argues that interactions at this accessible heparin binding site 
induce exposure of vitronectin' s N-terminal neoepitope. The N-terminal conformational 
changes are proposed to render PAI-1 and integrin binding sites available on the surface 
of the molecule. 
Heat or chaotrope-induced conformational changes in vitronectin are not limited 
to alterations in its tertiary structure. In fact, treatment of vitronectin with acid, 
chaotropic agents, and heat with subsequent refolding produces a multimeric form of 
vitronectin (Stockmann, et al., 1993). The formation of multimeric vitronectin has been 
studied extensively (Zhuang, et al., 1996; Bittorf, et al., 1993; Zhuang, et al., 1996). At 
both physiological pH and ionic strength, the folding and refolding curves of vitronectin 
exhibit hysteresis (Zhuang, et al., 1996). During refolding, unfolded vitronectin is in 
equilibrium with a partially folded intermediate, which has been found to have a high 
propensity to aggregate (fig. 1.5) The refolding pathway favors multimerization under 
most physiological conditions; however, the direction of the refolding equilibrium can be 
shifted towards the monomeric species in the presence of high salt concentrations. Salt 
disrupts electrostatic interactions required for monomeric stabilization and strengthens 
the intramolecular hydrophobic interactions that stabilize the monomeric species. 
The heparin-binding properties of native and multimeric vitronectin have been 
analyzed more extensively using fluorescence spectroscopy to determine the binding 
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V 4----~ _. V* 
Mv 
V: native, monomeric form 
V*: intermediate, partially folded 
U: fully unfolded monomer 
Mv: multimeric form 
Fig. 1-6: Cartoon illustrating the mechanism by which vitronectin forms higher order, 
muItimeric structures. 
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constant for the heparin interaction (Zhuang, et al., 1997). This data quantifies the 
binding constant for the vitronectin-heparin interaction (Zhuang, et al., 1997) and shows 
that the affinity for heparin is the same for either binding site in the native or multimeric 
vitronectin. The enhanced binding activity observed in denatured/renatured vitronectin is 
derived from the alignment of multiple binding sites on the surface of the refolded 
molecule rather than from increased exposure of the binding sites upon refolding. These 
studies provide evidence that the heparin considering the effects of multi valency when 
analyzing functional differences in native vs. multimeric vitronectin. It is incorrect to 
assume that the augmented affinity of multimeric vitronectin for ligands such as cells, 
monoclonal antibodies, or collagen results from exposure of neoepitopes without having 
considered the "Ve1cro-effect" that stems from clustered binding sites within higher order 
vitronectin complexes. 
Differential Localization: Multimeric vitronectin displays a higher effective 
binding activity towards a broad range of target ligands. Significantly, the stable 
multimeric conformer is not merely a phenomenon resulting from harsh treatment in 
vitro. Multimeric vitronectin is in fact produced in vivo. Vitronectin circulates in plasma 
predominately in a monomeric state, yet approximately 2% of circulating vitronectin is 
multimeric (Izumi, et at., 1998). In addition, higher order vitronectin complexes have 
been detected in the ECM (Stockman, et at., 1993), platelet releasates (Seiffert, et at., 
1996), and within the a granules of platelets (Seiffert, et at., 1996). P AI-1 and heparin 
have been shown to preferentially bind the ECM form of vitronectin, and platelet 
vitronectin displays affinity for P AI-1 that closely resemble that of multimeric vitronectin 
produced by denaturation (Mimuro, et at., 1997; Seiffert et at., 1996). 
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It is highly unlikely that oligomeric vitronectin IS generated in vivo VIa 
denaturation and renaturation, thus the physiological mechanism of vitronectin 
multimerization remains a topic of interest. It has been demonstrated that interactions 
with ligands such as C5b-7 or PAI-1 increase the affinity of vitronectin for 
glycosaminoglycans, cells, and collagen. The terminal complement complex contains 
multiple copies of vitronectin, as do TAT complexes (Preissner, et ai., 1987; Podack, et 
ai., 1979). It has recently been demonstrated that P AI-1-vitronectin complexes harbor 
more than a single molecule of vitronectin (Dec1ereck, et ai., 1988; Peterson, et ai., 
1998;). Thus, interaction with target ligands could possibly result in multimerization of 
vitronectin. 
Because vitronectin preferentially interacts with both collagen and elastin, 
conformationally altered vitronectin may be preferentially deposited in the matrix. A 
study has shown that conformationally altered vitronectin produced in vitro binds to 
endothelial cells in a glycosaminoglycans-dependent manner (de Boer, et al., 1992). By 
localizing vitronectin with immunogold, it was shown that multivalent forms of 
vitronectin were transcytosed by cells and incorporated into the matrix (Volker, et ai., 
1993). The multimeric form of vitronectin is also preferentially endocytosed by 
fibroblasts (Panetti, et ai., 1993; Panetti, et ai., 1995; Panetti, et ai., 1993). The CXv~5 
receptor mediates the endocytosis of ECM vitronectin. Within fibroblasts, vitronectin is 
degraded, which suggests a role for the fibroblast integrin receptors in tissue remodeling. 
Differential localization of the two forms of vitronectin may serve as a 
mechanism for regulating the function of the protein within different physiological 
environments. Once incorporated within the matrix, oligomeric vitronectin may localize 
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inflammatory, thrombotic, or fibrinolytic proteins to sites of injury at the endothelial 
vessel wall. 
Enzymatic Modification: Studies indicate that vitronectin activity may be 
controlled by intracellular or extracellular proteolysis. For example, when vitronectin is 
complexed with TAT, it is selectively endoctytosed and degraded within fibroblast cell 
lines, revealing a mechanism through which spent vitronectin might be removed from 
circulation. Extracellular proteolytic events may be effective for controlling vitronectin 
function as well. Cleavage of vitronectin with specific proteases such as thrombin and 
plasmin attenuates binding activity for glycosaminoglycans, and perhaps for other ligands 
as well. Plasmin degraded vitronectin has a high affinity for plasminogen. This high 
affinity may suggest a feedback loop mechanism for controlling activity at the site of 
wound healing. Plasma vitronectin normally would exhibit a prothrombotic effect by 
sustaining coagulation and inhibiting fibrinolysis. Plasmin and thrombin are highly 
concentrated in the vicinity of the thrombus. These proteases could cleave susceptible 
sites on vitronectin, attenuating heparin and P AI-1 binding function, thereby allowing 
clot lysis to continue. Moreover, plasminogen would be localized to the site of the vessel 
wall under such circumstances where it could be activated to degrade the fibrin clot. 
Matrix metaloproteinases-2, -3, -7 and -9 also degrade vitronectin (Imai, et al., 
1995). These proteases degrade ECM components like collagen, fibronectin, and 
laminin. The functional significance of the degradation has not been demonstrated, but it 
is likely to be important for ECM remodeling. Vitronectin induces MMP-2 expression in 
melanoma cells via the aY~3 integrin receptor (Seftor, et al., 1993). This vitronectin-
induced MMP-2 stimulation would explain the invasive properties of cancerous cells. 
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The overexpressed MMP-2 would degrade vitronectin and other matrix components, 
thereby releasing tumor cells from the matrix. 
A platelet membrane protease has also been shown to degrade vitronectin. 
Calpains I and II are expressed on the surface of platelet membranes (Kambayashi, et al., 
1989). Upon membrane damage induced by freeze thaw methods or by addition of 
nonionic detergent, calpain activity was stimulated, degrading both platelet and 
exogenously applied vitronectin (Seiffert 1996). Limited digestion with calpain reduced 
the PAl-I, heparin, and cell binding activities of vitronectin. Thus, platelet injury made 
lead to proteolytic events that reduce vitronectin activity. 
Interestingly, endogenous proteolytic cleavage of vitronectin occurs at position 44 
(releasing the somatomedin B domain) and at position 379; however, not all vitronectin is 
susceptible to the C-terminal cleavage. A genetic polymorphism at position 381 
determines the sensitivity of vitronectin to proteolysis at this position. The presence of 
methionine at position 381 is associated with single-chain vitronectin, whereas threonine 
at position 381 increases the susceptibility to cleavage at the 379-380 peptide bond 
(Tollefsen, et al., 1990). Each of the alleles is present at a frequency of approximately 
50% in white populations (Conlan, et al., 1988). Approximately 18% of people are 
homozygous for the single chain vitronectin allele, and 22% are homozygous for two-
chain vitronectin. Heterozygotes represent 590/0 of the population. While endogenous 
removal of the somatomedin B domain has been shown to decrease affinity for PAI-1 
(Sigurdardottir, et al., 1994), it is not known whether cleavage at 379 affects vitronectin 
activity. 
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Post-translational chemical modification of vitronectin may also playa role in 
regulating its activity. Protein kinase A dependent serine phosphorylation occurs within 
the heparin binding sequence ofvitronectin both in vitro and in vivo. It has been 
suggested that the phosphorylated form ofvitronectin may exhibit altered binding activity 
towards ligands that bind to the arginine-rich C-terminal sequence (Gechtman, et al., 
1997; Chain, et al., 1990; Sane, et al., 1991; Preissner, et al., 1990; Peake, et al., 1996). 
Treatment of vitronectin with factor XIIla or tans glutaminase in vitro results in the 
formation of covalently-crosslinked multimers, which display increased affinity for P AI-
l. 
Computational Model 
We recently proposed a model of vitronectin ·using computational methods ( Xu, 
et al., 2001). In this approach, we adopted the domain assignment described previously 
for the N-terminal, central and heparin-binding domains, and predicted the structure of 
each domain separately. Fold recognition through sequence-structure alignment 
(threading) ( Xu, et al., 1998) was used for the structural modeling. The predicted 
structures for the three domains using this method are shown in Fig.1-7, Panels a, band c. 
As shown in the linear schematic of vitronectin in Fig. 1-7 d, the structural models for the 
domains do not include the connecting region between the N-terminal and central 
domains, which is predicted to be highly unstructured. 
The central domain (residues 129-323) is modeled as a full 4-bladed ~-propeller 
fold similar to that seen in gelatinase A (Gohlke, et al., 1996), collagenase ( Gomis-Ruth, 
et aI., 1996) and hemopexin ( Faber, et al., 1995). The threading results for the C-
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Fig. 1-7: Structural models of vitronectin. (a-<:) show the structural models of the N-tenninal 
somatomedin B domain, the central domain with a four-bladed b-propeller fold, and the C-tenninal 
heparin-binding domain, respectively. The color from the red to blue shows the sequence order from the N-
terminus to the C-terminus. The yellow solid spheres indicate cysteines. White spheres (a) show the 
integrin attachment site; red spheres (b) show glycosylation sites (residues 150 and 223); and thin lines (c) 
show the heparin-binding site. d: Linear representation of the sequence of vitronectin, with blue 
highlighting corresponding to domains modeled in (a-<:), yellow dots indicating cysteines, red structures 
representing carbohydrate attachment sites, and the white arrow pointing to the known site of protease 
cleavage to the two-chain form. e: Docking structure between the central (blue) and C-terminal (yellow) 
domains, with cysteines (red lines), presumed heparin-binding residues (354-363 in white ribbons), sites 
susceptible to protease (residues 305, 361, 370, 379 and 383 with light blue spheres), and N-linked 
glycosylation sites (residues 150 and 223 with green spheres). f,g: Predicted docking the N-terminal, 
central and heparin-binding domains, and predicted the structure of each domain separately. 
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terminal domain segment of residues 354-456 indicated that the best hit for this domain 
was also the PDB entry 1gen (C-terminal end of gelatinase A). However, the sequence 
segment covers only half of the 4-bladed ~-propeller fold. The threading method, which 
is an algorithm that samples all of the structural entries in the PDB to arrive at a given 
model (Xu, et al., 2001; Xu, et aI., 1998), thus agrees with the early report of distant 
homology with hemopexin based on patterns within the repeated sequence motifs that we 
now know comprise the propeller blades (Jenne, et al., 1987). The predicted structure for 
the N-terminal domain (residues 1-53) is an open 5-stranded ~-barrel fold that is rich in 
disulfide bonds. 
In further work, we have docked the central and C-terminal domains together to 
gain insight into the overall fold of the protein (Fig 1-7e). An inter-domain disulfide was 
used to constrain the docking, and our model was tested for agreement with numerous 
biochemical results. In particular, the orientation of the heparin-binding domain (Gibson, 
et al., 1999), burial of known free sulfhydryls (Zhuang, et al., 1996), and the positioning 
of glycosylation sites (Ogawa, et al., 1995) were considered. The known heparin-binding 
sequence appears in the model to lie within a groove between the two domains, with 
suitable dimensions for binding of heparin. Two positively charged arginine residues lie 
at the base of this binding pocket; we have shown that these two residues exhibit 
intermolecular nuclear Overhauser effects (NOEs) with heparin in nuclear magnetic 
resonance (NMR) experiments with a peptide from the heparin-binding region from 
vitronectin (Gibson, et al., 1999). The participation of the two domains to form the 
heparin-binding site in the model is consistent with a report using recombinant fragments 
from vitronectin that assigns weak heparin-binding function to the central domain 
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(Yoneda, et ai., 1998). To test this predicted binding site, we also docked heparin 
together with the two-domain protein model (Fig. 1-7, Panels f and g) and observed a 
good fit of the ligand in the binding pocket. These modeling results are compelling and 
provide impetus for an experimental confinnation of the predictions. 
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Chapter 2 
CRYSTALLIZATION/CO-CRYSTALLIZATION OF FULL-
LENGTH, NATIVE, MONOMERIC VITRONECTIN 
Introduction 
Human vitronectin has the intriguing capability of interacting with a broad 
spectrum of ligands, which in tum gives it the ability to regulate an array of physiological 
processes. The form of vitronectin found in circulation is important in pathological 
situations or in cancer metastasis and tissue remodeling by its association with the 
vascular extracellular matrix. Presently, a thorough understanding of the control 
mechanisms governing vitronectin's macromolecular binding and therefore its 
characteristic activities both in circulation and the ECM is still being sought after 
empirically. 
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Research within our lab is based on several hypotheses: Vitronectin is a multi-
domain protein with distributed binding sites to control the dynamic processes of 
coagulation vs. fibrinolysis and binding vs. release from the matrix. Complexes of 
vitronectin with biological targets associate into higher-order structures with altered 
functions and tissue compartmentalization. Vitronectin complexes are recognized by 
cell-surface receptors, with a preference for higher-order complexes over free, 
monomeric vitronectin. 
From investigations into vitronectin structure/function relationship, a model has 
emerged in which vitronectin is organized into several domains that provide the extensive 
repertoire of binding epitopes for target ligands. As our lab has progressed in ligand-
binding work, we have realized the value of a structural model in guiding our 
understanding of vitronectin and its interactions with target molecules. We recently 
proposed a structural model of vitronectin using computational methods (threading). 
These modeling results are compelling and provide impetus for an experimental 
confirmation of the predictions. I have focused my research primarily on the 
crystallization of vitronectin, for as encouraging as the computational predictions for 
vitronectin structure are, we are cautious and must validate the model experimentally. 
Crystallization is a way by which a metastable, supersaturated solution can reach 
a stable, lower energy state via reduction of solute concentration (Weber, et at., 1991). 
Relative to their state in solution, crystallization generally lowers the free energy of 
proteins by approximately 3-6 kcal/mole (Drenth, et at., 1992). The general processes by 
which substances crystallize are similar for molecules of both microscopic (salts) and 
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macroscopic (proteins) dimensions. There are three stages of crystallization common to 
all systems: 1) nucleation, 2) growth, and 3) growth termination. 
It is entirely by chance that solvated molecules will associate at any given time 
with the appropriate geometric orientations required to form an aggregate nucleus. After 
this event is achieved, however, the newly formed nucleus can serve as a platform on 
which further protein macromolecules can be adsorbed and geometrically aligned to form 
an ordered crystal lattice. After crystallization has been initiated, it is not ensured that the 
crystal will inevitably continue to grow. The probability of crystal growth is dependent 
upon such factors as solute concentration, temperature, the nature of the chemical used to 
induce precipitation, pH, as well as other physical and chemical factors. The 
concentration of successfully formed nuclei directly affects the outcome of 
crystallization. Conditions that induce the formation of only a few nuclei must be 
achieved in order to produce crystals suitable for subsequent X-ray diffraction studies 
(0.1-0.3 mm). 
The nucleation event involves the association of solvated molecules or non-
crystalline aggregates (i.e. oligomers) in a manner that produces a thermodynamically 
stable aggregate with a characteristic repeating lattice. Nucleation from supersaturated 
protein solutions does not always necessitate formation of macroscopic crystals. The 
protein aggregate must first exceed a critical size defined by its surface area to volume 
ratio (Feher, et al., 1985; Boistelle, et al., 1988). Having met this size-dependent 
criterion, the aggregate nucleus is then capable of further growth. If at any time, 
however, the nucleus falls beneath this critical size, it will spontaneously dissolute. The 
phenomenon of amorphous precipitation does not involve surface area to volume 
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competition, and so it generally takes significantly less time to occur relative to 
crystallization. 
The degree of nucleation is determined by the degree of solute supersaturation. 
Moreover, the extent of supersaturation is in tum related to the protein's overall 
solubility. Higher solubility allows for an increased frequency of diffusional collisions. 
Higher degrees of supersaturation produce more stable aggregates and will therefore 
increase the likelihood of stable nuclei formation. This condition generally facilitates 
excessive production of small crystals in solutions in which solute molecules are overly 
available. In this case, there will be a depletion of solvated protein available for 
association making the attainment of large, diffraction quality species impossible. At 
lower solute concentrations, however, the frequency with which individual, stable nuclei 
are formed decreases, and the formation of individual crystals is favored. 
Molecular deposition onto the nucleus is an exceptionally dynamic process. The 
more specific interactions a solvated protein molecule forms as it associates with the 
growing crystal, the tighter will the binding be as a result of a lower free energy of 
formation. A low energy value will in tum give rise to greater crystalline stability. 
Successful protein crystallization depends highly on the purity of the sample 
being used. Due to the use of small volumes in the vapor diffusion method, any 
impurities within a sample will be present in relatively high concentration leading to 
contamination of the crystal lattice and ultimately poor crystals. 
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Problems: 
Crystallization assumes that identical, macromolecular protein units are available 
within the drop to be incorporated into an ordered crystal lattice. A significant problem 
in obtaining crystallographic/structural information for native vitronectin comes from the 
inability to acquire a homogeneous sample due to factors such as proteolytic cleavage, 
glycosylation, phosphorylation, and formation of higher order species. 
Vitronectin is purified from pooled human plasma that contains both single and 
double chain structural forms (Zhuang, et al., 1997). In vivo, vitronectin can exist in a 
full-length or a two-chain, cleaved form. Cleavage occurs by an unidentified trypsin-like 
protease, which cuts vitronectin just beyond the heparin-binding domain at arginine 379 
(Tollefsen, et al., 1990). The presence of threonine versus methionine at position 381 
increases the likelihood that vitronectin will be cleaved at position 379. The cleaved 
molecule is a two-chain form of vitronectin: a 62 kDa N-terminal heavy chain and a 10 
kDa C-terminal light chain. A single disulfide bond holds the two chains together. The 
72 kDa and 62 kDa forms of vitronectin can be seen on the Coomassie-stained SDS-
PAGE gel in figure 2-1, panel A, and on the reversed-phase HPLC chromatograph, panel 
B. Although it is generally assumed that the two forms of vitronectin are functionally 
indistinguishable, this premise has not been proven empirically. 
The formation of crystal lattice contacts (Fig. 2-2, panel A) relies heavily on 
protein sample homogeneity. In a heterogeneous sample, the protein will be less 
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Fig. 2-1: Panel A: A 10% SDS-PAGE Coomassie-stained gel shows the presence of the 72 kDa and 62 kDa forms of vitronectin. Panel B: the 72 kDa and 62 kDa forms of vitronectin seen by reversed-phase HPLC. 
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Specific Protein-Protein 
Lattice Contacts 
Non-specific, Weak, 
Protein-Protein Contacts 
Fig. 2-2: Panel A illustrates stabilized, r epeating, protein-protein lattice contacts 
requisite for crystal formation and subsequent growth. Panel B illustrates the weak, 
non-repeating, protein-protein contacts (yellow), which arise from structural heterogeneity (one and two chain structur al forrns) of the protein sample. 
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capable of making the necessary ordered protein-protein contacts for nucleation and 
therefore may never crystallize regardless of how many screens are performed. 
A vitronectin sample free of protein impurities is pure in the sense that vitronectin 
is the only protein species present in the sample; however, due to the presence of both the 
one and two chain forms, the vitronectin sample remains "impure" due to stnlctural 
heterogeneity. Such structural heterogeneity can prevent the formation of proper lattice 
contacts and instead force the protein molecules to assemble in an unordered fashion via 
weak, non-repeating molecular contacts, often times leading to amorphous precipitation 
of the protein (Fig. 2.2, panel B). To date, there is not an efficient method for separating 
the two vitronectin forms in the amount requisite for crystal screening. 
Extensive post-translational, chemical modification leads to a high degree of 
heterogeneity in vitronectin samples and thus poses a problem for crystallographic 
studies. Vitronectin undergoes N-linked glycosylation at Asn residues 67, 150, and 223. 
Glycosylation renders a protein more soluble, reduces its likelihood to aggregate, and 
light dynamic scattering experiments reveal that glycosylated proteins are monodisperse 
(Rudd, et al., 1997). Although each of these glycoprotein characteristics are desirable for 
crystallization, glycosylated proteins often contain heterogeneous carbohydrate, and, as 
previously mentioned, heterogeneity lessens the likelihood for protein crystallization 
(Stura, et al., 1992). Thus, glycoproteins are often times difficult to crystallize. Standard 
enzymatic and chemical methods for removing protein carbohydrate were extensively 
employed with vitronectin without success. Nevertheless, crystal screens were still 
performed. 
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Experimental Procedures: 
Preparation of a Full-Length, Monomeric Vitronectin Sample for Screening 
Studies: Vitronectin was purified from human plasma by a modification of the original 
protocol of Dahlback and Podack (Dahlback, et al., 1985). One milligram of vitronectin 
from a precipitated ammonium sulfate slurry was dialyzed extensively against a .02 M 
Tris, .1 M NaCl solution, pH 7.4 at 4°C. Purity of the vitronectin sample was analyzed 
using SDS-PAGE. The vitronectin sample was concentrated to approximately 10 mg/ml 
using a .5 Ultrafree 30,000TM MWCO centrifugal concentration device. Prior to 
screening, any amorphous material present in the sample was removed by centrifugation 
at 10,000 RPM at 4°C. 
Crystal Screening: Screening of crystallization conditions for full-length, 
monomeric vitronectin was perfonned using the hanging-drop vapor-diffusion method 
using both Crystal Screen™ and Index™ crystal screens commercially available from 
Hampton Research. Crystal Screen™ is a 50 condition, sparse matrix-based crystal 
screen that allows the testing of wide ranges of pH, salts, and precipitants using a very 
small sample of macromolecule (J ancarik, et al., 1991). 
Index™ is a 96 reagent screen that combines the strategies of the grid screen, 
sparse matrix, and incomplete factorial with classical, contemporary, and novel 
crystallization reagent systems. Index™ samples the classical and often effective reagent 
ammonium sulfate in a grid screen fonnat across a pH range of 3.5 to 8.5. Classical salts 
such as sodium chloride, phosphate, and fonnate are also sampled across a broad range of 
pH. 
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The concentration of vitronectin samples used for crystal screening were between 
10 and 15 mg/ml as determined by absorption at 280 nm. All screens were performed at 
4°C to prolong vitronectin stability within the drop. 24-well VDXTM plates purchased 
from Hampton Research were prepared for hanging drop vapor diffusion by applying 
vacuum grease around the edges of the reservoirs. 1 000 ~l of each screening reagent was 
pipetted into the VDXTM plate reservoirs. 1.0)..11 of concentrated vitronectin was pipetted 
onto the center of a 22 mm siliconized, circle cover slide, and 1.0 )..11 of screening reagent 
was subsequently removed from each reservoir and pipetted into the protein sample 
droplet on the siliconized cover slide. Instead of adding the vitronectin drop to the 
precipitant drop, precipitant was added to the vitronectin drop so as to avoid precipitation 
due to the sudden exposure of vitronectin to a very high precipitate concentration. Cover 
slides were then inverted, placing the droplets over the reagent reservoirs, and the cover 
slides were sealed to the reservoirs' edges. 
Screen Drop Interpretation: Each of the crystallization experiments was 
examined using a stereomicroscope immediately after setting up each screen, everyday 
for one week following the setup, and once a week thereafter. Each individual drop was 
examined and all observations were recorded. I chose to simplify my data record keeping 
by adopting a one number drop scoring method described by Bergfors, et aI., wherein a 
numerical score (1-9) is recorded for each drop condition within a screen. Figure 2-3 
illustrates the numerical representation used to score the large number of screen 
conditions. 
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Score Drop Phenomena 
(0) 
- clear drop 
(1) 
- non-proteinacious particle 
(glass/fibers) (2) 
- light precipitation! drop mostly 
clear 
(3) 
- fully precipitated protein (3) 
- precipitation upon mixing with 
viscous well solution (3) 
- wrinkled skin/denatured protein 
(4) 
- gelatinous protein-precipitate (4) 
- gelatinous protein 
(5) 
- phase separation 
(6) 
- spherulites (6) 
- transparent cluster (6) 
- microcrystals 
(7) 
- needles 
(8) 
- plates 
(9) 
- crystals 
Fig. 2-3: Numerical representations for crystal screen condition scoring. 
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During the screening for vitronectin crystallization conditions, any drops observed 
that remained clear (score of 0) for a period longer than two weeks were removed and 
placed over a reservoir containing the same condition but with a higher precipitant 
concentration. Drops that, after two weeks, were mostly clear but contained precipitated 
vitronectin (score of 2) were recorded so as to avoid repeating these particular conditions 
in future screens. The rationale for avoiding these conditions in future screens is that 
either the vitronectin or precipitate concentrations within these drops most likely does not 
favor nucleation/crystal growth. Dark drops in which vitronectin fully precipitated (score 
of 3) within one day were recorded so that these conditions could be repeated in future 
screens with half the precipitate concentration. Conditions containing heavy vitronectin 
precipitate after approximately one week donot favor crystallization and were avoided in 
future vitronectin screens. 
Results and Discussion: 
Four vitronectin crystal screens were performed using Crystal Screen™, two with 
a 10 mg/ml vitronectin sample and two with a 15 mg/ml sample. In addition, two 
Index™ screens were performed using one 1 0 mg/ml vitronectin sample and one 15 
mg/ml sample. Condition 19 of Crystal Screen™ (0.2 M Ammonium Acetate, 0.1 M Tris 
Hydrochloride pH 8.5, 30% v/v iso-Propanol) produced 3 micron x 3 micron 
microcrystals, which ceased growing after approximately four weeks. Attempts to 
optimize around this condition have not yet been performed due to scarcity of protein. 
The majority of conditions in both Crystal Screen™ screens produced amorphous 
precipitate within the first week for both vitronectin concentrations screened. Index™ 
produced a number of conditions containing protein gel mixtures and spherulites in both 
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protein concentrations screened; therefore Index™ screen shows more promise for 
vitronectin crystallization than does Crystal Screen™, for full vitronectin precipitation 
was observed in only approximately 55% of the conditions. 
Vitronectin Co-crystallization 
Rationale: Sparse matrix crystal screenIng generally yields crystals only for 
proteins that crystallize with facility. Such proteins are capable of readily forming the 
stable protein-protein interactions requisite for crystal lattice formation. Unfortunately, a 
large proportion of proteins do not fall within this category. By increasing the number of 
crystallization trials, diminished returns are reaped such that the augmented effort is 
difficult to justify. Because vitronectin has been such a difficult protein to crystallize, the 
possibility of employing a scaffold for protein crystallization becomes enticing. One 
such scaffold approach is based upon the use of immunoglobulin (IgG) fragments, 
wherein the protein of interest is the antigen recognized by the IgG. The system 
envisaged is one consisting of approximately two stages: 1) the screening for an 
appropriate scaffold IgG fragment, and 2) the optimization of the scaffold system for 
diffraction quality crystals. 
Immunoglobulins are known to create a specific and stable complex with the 
epitope of their target protein and, owing to their high affinity, are used as a tool for 
Enzyme Linked Immunosorbant Assay (ELISA) and Western blotting analysis to detect 
tiny amounts of protein. The tertiary structures of IgG antigen-binding fragments 
complexed with antigens have been investigated in detail (Silverton, et aI., 1984; Laver, 
et aI., 1990; Ostermeier, et aI., 1995). 
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Fab and F( ab)'2 fragments can be used as co-crystallization agents even in the 
crystallization of highly deterrent membrane proteins (fig. 3-1) (Ostermeier, et at., 1995). 
Such antibody fragments are very soluble and bind specifically to antigens with 
reasonable equilibrium constants. IgG fragments can, in some instances, effectively 
transform aggregated protein into a soluble, monodispersed protein sample suitable for 
crystallization trials. It has also been found that IgG fragments can immobilize a region 
of a protein thereby reducing sample flexibility and enhancing sample conformational 
homogeneity, which enhances chances for crystallization (Stura, et ai., 2001a). With 
recent improvements in the use of molecular replacement (MR) , the structure 
determination of IgG-antigen complexes can proceed at a relatively quick pace. For this 
proj ect, crystallization of vitronectin and subsequent structure determination is directed 
primarily towards the use of Fab fragments as a co-crystallization agent. The rationale 
behind the use of Fab fragments remains linked both to the ease with which the structure 
ofFab fragments have been determined and to the difficulties that have been presented by 
the crystallization with either whole IgG or other IgG fragments (Haynes, et ai., 1994; 
Zhou, et ai., 1994). This difficulty is believed to be due to the flexibility or 
conformational heterogeneity of the IgG due to the various disulfide-linked chains as well 
as to added heterogeneity from Fc fragment glycosylation. F(ab)'2 fragments share some 
of the same problems mainly because of the degree of heterogeneity that may result from 
proteolytic cleavage used to fragment the IgG, the flexibility in elbow regions, and in 
some cases glycosylation. Nevertheless, F( ab )'2 fragments, specifically their reduced 
F( ab )' form, have been shown to serve as successful scaffolds for protein crystallization 
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Fig. 3-1: Antigen-Fab Crystal Packing. KcsA (yellow) was crystallized as a complex 
with an antibody Fab fragment (blue) at 2.8A resolution. The image is a view down the four-fold crystallographic axis of the 14 cell, which corresponds to the molecular four-fold axis of the K + channel (Zhou, eta/., 2001). 
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and therefore will be used in addition to Fab fragments as a scaffold candidate for 
vitronectin crystal screens (fig. 3-2). 
Problems 
Theoretically, the size of a protein that can be accommodated by the scaffold is 
limited, even in one-dimension. Furthermore, the size of the protein must be small 
enough so as to not disturb the packing of the scaffold. For example, a protein such as 
vitronectin that forms multimeric complexes could disrupt the correct alignment of the 
scaffold. In light of this problem, stoichiometry variation of the vitronectin-IgG fragment 
complex will be performed in screening as described by Stura, et al., 2001 b. 
An example of the stoichiometry variation phenomenon was found In the 
crystallization of Fab 2A2 in complex with protein SpA. In the crystallization of this 
complex, Stura, et al. found that the addition of extra scaffold proteins helped to 
overcome problems that arose when the added SpA protein dimerized (Stura, et aI., 
2002). The crystals of the Fab 2A2-SpA complex showed a 3:2 stoichiometry with two 
Fab fragments complexed and one free (Graille, et al., 2000). The two SpA molecules 
dimerized and forced the dimerization of two of the three Fabs in the asymmetric unit. 
Without the extra copy of Fab 2A2, it would not be possible to maintain the "scaffold" 
direction which in the complex replicates the packing found in crystals of the 
uncomplexed Fab (Stura, et al., 2001 b). Changing the stoichiometry alleviates size and 
polymerization problems: as the complex gets larger, the concentration of scaffold 
protein is increased. In the Fab 2A2-SpA example (Graille, et al., 2000), the free Fab in 
the lattice of the 2A2-SpA complex packed along one lattice direction in the same 
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Fig. 3-2: Location of the Fab molecules in the P21 crystal lattice of the TPOI63-Fab complex. Light-colored Fab molecules and dark colored Fab molecules are anti-parallel. The box indicates the unit cell (Kraulis, 1991). 
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manner as it did in the crystal of uncomplexed 2A2 suggesting that one-dimensional 
scaffolds could be generated as the stoichiometry is varied. Unfortunately, a one-
dimensional scaffold does not exist. 
To make the transition from a one-dimensional scaffold to one of three 
dimensions, there must be some propensity within the system to create the other 
remaining lattice interactions. With an increase in the number of directions, the number 
of restrictions increases as well. In a two dimensional case, translational and rotational 
symmetries must be respected in both dimensions. A "guest" antigen that does not 
respect such constraints is likely to disrupt the integrity of the scaffold. Thus, screening 
for the correct IgG fragment scaffold with which to crystallize vitronectin will be carried 
out in order to determine a suitable scaffold lattice for vitronectin. 
IgG Antibody structure 
An IgG molecule is made up of two Fab fragments responsible for antigen 
binding and one Fc fragment responsible for activation of complement. Figure 3-3 
illustrates a space filling model of a murine IgG2a molecule with its Fab and Fc fragments 
labeled. IgG proteins are composed of two heavy chains and two light chains. The fold 
of the immunoglobulin domain is a highly conserved motif. The Fab portion is 
composed of two variable and two constant domains (Rousseaux, et al., 1983). The Fc 
fragment is made up of four constant domains. The variable and constant domains have 
similar structures, but the variable domains have two extra ~-strands (Rousseaux, et al., 
1983). The variable regions were named based on their regions ofhypervariable amino 
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Fab Fab 
Fc 
Fig. 3-3: The image is a space filling model of mouse IgG2a. The two heavy chains are shown in yellow and light blue whilst the two light chains are shown in green and dark blue. The carbohydrate (red and green) is visible in the Fc fragment (Harris, et ai., 1997). 
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acid sequence, which correspond to the antigen-binding site. In all Fab/antigen structures 
studied so far, the following general observations have been made. 1) Good structural 
complementarity exists between the binding surfaces of antibody and antigen; 2) 
recognition is assisted by salt bridges and hydrogen bonds between residues in the 
antigen binding site; and 3) hydrophobic effects and water molecules may playa role in 
recognition. 
Experimental Procedures 
Materials: Vitronectin was purified from human plasma by a modification of the 
original protocol of Dahlback and Podack (Dahlback, et at., 1985). 10 mg of a murine, 
anti-vitronectin IgG2a monoclonal antibody (GMA90o) was generously provided by Dr. 
Bill Church of Green Mountain Antibodies in Burlington, Vermont in exchange for 2.0 
mg of human, monomeric vitronectin antigen. The antibody was purified by gel filtration 
and ion exchange chromatography from murine ascites. The purity of the monoclonal 
antibody sample was determined by 10% SDS-PAGE. Crystal Screen™, Index™, and 
Low Ionic Strength™ protein crystal screens were purchased from Hampton Research. 
Both the ImmunoPure Fab Preparation KitTM and the ImmunoPure F(ab')2 Preparation 
KitTM were purchased from Pierce Biotechnology. Plastic microtiter plates (Immunolon) 
were a product of Coming. 
Determining the Titer of GMA 900 Monoclonal Antibody via ELISA: Vitronectin 
was purified from human plasma by a modification of the original protocol of Dahlback 
and Podack (Dahlback, et at., 1985). A microtiter plate was coated with a 5 /-tg/ml 
vitronectin solution in 50 mM sodium carbonate (NaC03), pH 8.5 as the coating buffer. 
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100 ).11 of the vitronectin/coating buffer solution was added to each well. The microtiter 
plate was covered tightly with parafilm and held at room temperature for 4 hours. 
The solution was emptied from the wells by shaking the microtiter plate into the 
sink and subsequently blotted dry on paper towels. The microtiter wells were then 
washed 3 times with IX TBS, pH 7.4 and blotted dry between each rinse. Each well was 
then filled with 200 ).11 of a 2% BSA blocking solution in TBS and set at room 
temperature to block for one hour. After blocking with 2% BSA, the microtiter plate was 
washed 3 times as described earlier. A serial dilution of monoclonal antibody (mAB) 
GMA900 was set up. 100).11 TBS with 0.2% BSA was pipetted into all wells in row one. 
50 ).11 TBS containing 0.2% BSA was pipetted into all wells in 3 through 12. The mAB 
was diluted to a concentration of 10 ).1g/ml in TBS containing 0.2% BSA, and 100 ).11 of 
this antibody solution was added to wells A through H in row 2. 50).11 were removed 
from all of the wells in row 2 and subsequently mixed with the TBS buffer in row 3. In 
the same fashion, the monoclonal antibody solution was serially diluted through row 12. 
After 50 ).11 of antibody was mixed from row 11 with the buffer in row 12, a final 50 ).11 
volume was removed from all wells in row 12 and discarded. The serially diluted 
monoclonal antibody was allowed to sit for one hour at room temperature to facilitate 
mAB binding to the vitronectin antigen. 
The microtiter plate was again washed with TBS as previously described. An 
anti-mouse peroxidase-linked secondary antibody (Vector Laboratories) was diluted 
1:1000 in TBS containing 0.2% BSA. 100).11 of the diluted secondary antibody was 
pipetted into all wells. Again, the microtiter plate was allowed to sit for one hour at room 
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temperature to facilitate the binding of the secondary antibody to the primary monoclonal 
antibody. The plate was rinsed with TBS as described previously, and developing 
solution was made fresh by combining 100 ml of a 50 mM sodium citrate buffer, pH 5.5 
with 20 mg of 2,2'-azino-bis(3-ethylbenzy-thiazoline06-sulfonc acid) diammonium salt 
(ABTS), and 50 }ll of a 30% hydrogen peroxide solution. 100 }ll of developing solution 
was pipetted into each well. The plate was allowed to develop in a Wallace 100™ 
microtiter plate reader for 30 minutes at room temperature. The plate was read with the 
wavelength set at 405 nm. Absorbance was measured every 5 minutes for 30 minutes to 
ensure readings were obtained within the linear range of the instrument. As shown in 
figure 3-3, the titer of the GMA900 monoclonal antibody was determined to be 
approximately 1-5 }lg/ml. 
Preparation and Purification of Fab Fraglnents: The GMA900 mAB was 
dialyzed extensively against a 20 mM sodium phosphatell 0 mM EDT A buffer at pH 7.0, 
and concentrated to approximately 5 mg/ml. 0.5 ml of the mAB sample was added to 0.5 
ml of digestion buffer (42 mg cysteine-HCI dissolved in 12 ml of the Phosphate Buffer, 
pH 10). Immobilized papain was equilibrated by adding 0.5 ml of the 50% immobilized 
papain (0.25 ml of immobilized papain) to a glass test tube, and 4.0 ml of digestion 
buffer were added. The papain was separated from the buffer using a serum separator 
tube, and the immobilized papain was resuspended in 0.5 ml of digestion buffer. 1.0 ml 
of mAB sample was added to the tube containing the immobilized papain and was 
incubated for 5 hours at 37°C while maintaining constant mixing at high speed. The 
solubilized Fab and Fc fragments and undigested IgG were recovered from the 
immobilized papain gel using a serum separator tube described above. The crude digest 
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2 3 4 5 6 7 8 9 
0.053 0.252 0.256 0.218 0.252 0.245 0.207 0.171 0.146 
0.056 0.267 0.262 0.25 0.259 0.232 0.214 0.179 0.145 
0.056 0.281 0.285 0.244 0.264 0.236 0.214 0.179 0.147 
0.055 0.271 0.27 0.236 0.255 0.246 0.213 0.181 0.146 
0.055 0.276 0.272 0.23 0.262 0.236 0.222 0.182 0.147 
0.056 0.281 0.272 0.246 0.263 0.245 0.218 0.183 0.147 
0.054 0.282 0.281 0.254 0.254 0.245 0.214 0.181 0.147 
0.054 0.286 0.287 0.258 0.274 0.244 0.22 0.181 0.149 
Fig. 3-4: Direct ELISA to measure the titer of GMA900 Anti-Vitronectin Monoclonal 
Antibody. Titer determined to be approximately 1-5 0 g/ml. 
10 11 
0.111 0.088 
0.117 0.088 
0.112 0.087 
0.111 0.087 
0.114 0.088 
0.113 0.088 
0.12 0.095 
0.121 0.093 
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was collected in a clean tube. For maXImum recovery of fragments, the 
immobilized papain was washed with 1.5 ml of ImmunoPure® IgG Binding Buffer, and 
the wash was combined with the crude digest to give a 3.0 ml sample. The Fab 
fragments were initially purified using affinity chromatography with an AffinityPak™ 
protein A column as the initial purification step followed by gel filtration 
chromatography using an 18 ml column packed with Sephacryl S-100TM High Resolution 
Resin. 
Did the Proteolytic Fragments Retain Antigen Binding Property? Proteolytic 
cleavage of IgG molecules has been found to occasionally produce Fab fragments that, 
while still structurally intact, do not retain their antigen binding properties. Because the 
function of IgG fragment-based scaffold for protein crystallization relies entirely on the 
Fab fragments' ability to bind its antigen tightly, fragments that lose their antigen binding 
ability following proteolysis will never facilitate the crystallization of a host protein. 
Thus, it is crucial to assay the monoclonal antibody fragments for antigen binding 
potential. 
The vitronectin binding potential of the purified Fab fragments will be assayed by 
gel filtration HPLC using a Phenomenex BioSep-SEC-S2000™ column. Vitronectin will 
be mixed with purified monoclonal Fab fragments in differing molar ratios. Binding will 
be assayed based on protein sample elution times. After characterizing the elution times 
of protein standards covering the linear molecular weight range, both vitronectin and Fab 
will be injected separately, and the characteristic elution times of each sample will be 
recorded. 
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By injecting a sample containing vitronectin and Fab fragments, the degree of 
binding can be quantitatively determined. If the Fab fragments bind the vitronectin, a 
new elution-time peak representing the vitronectin-Fab complex will appear. By 
integrating the area under the elution-time peaks, the extent of binding can be determined 
by assessing the integrated elution peak ratios. If the Fab fragments do not retain their 
antigen binding property, there will be two elution-time peaks on the chromatograph 
representing uncomplexed Fab and vitronectin identical to the elution times determined 
previously for each species independently. In contrast, if 1000/0 of both protein samples 
participate in complex formation, one elution peak characteristic of a higher molecular 
weight species of approximately 120 kDa (72 for vitronectin + 50 for Fab fragments) will 
be observed. 
Determination of Vitronectin-IgG Fragment Stoichiometry and Optimization of 
Contplex Formation 
If it is determined that the Fab fragments did in fact retain their antigen binding 
property, determination of the vitronectin-IgG Fragment binding stoichiometry and 
optimization of complex formation will be determined USIng analytical 
ultracentrifugation sedimentation equilibrium experiments carried out at 277 K on a 
Beckmann Optima XL-A instrument. 100 ml aliquots will be centrifuged at 50,000 
RPM. Radial scans of the absorbance at 280 nm will be taken at different time intervals. 
The distribution of a single, homogeneous species within the ultracentrifuge cell at , 
equilibrium is given by, 
Cr = cmexp( 0-) + base 
(J = M(l- JJ p)o}(r2 _r2 rrJl2RT 
(Eq. 1) 
(Eq.2) 
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in which Cr and Cm are the concentrations of the protein at radial position, r, and at a 
reference position (i.e. the meniscus), respectively, within the cell. M is the protein 
molecular weight, ;; is the partial specific volume, w is the angular velocity, P is solvent 
density, r is the distance in cm from the center of the rotor, r m is the radial position in cm 
of the reference from the center of rotation, R is the gas constant, and T is absolute 
temperature. The "base" term is a constant that corrects for non-sedimenting baseline 
absorbance (or fringes measured). The partial specific volume will be calculated from the 
composition of vitronectin and Fab, and its use for analysis of equilibrium centrifugation 
data will yield reliable molecular weights for the isolated monomeric proteins using 
Equation 1. The calculation of partial specific volume for vitronectin from its amino acid 
and oligosaccharide composition was previously reported and used in published 
ultracentrifugation analyses on vitronectin (Zhuang, et al., 1996). For an associating 
system, at chemical and sedimentation equilibrium, in which, for example, A + B .~. AB, 
the sedimentation behavior of each individual macromolecular species, A, B, and AB, is 
also given by the exponential distribution described above (Hensley 1996). The total 
macromolecule concentration at any radial position is equal to the sum of all of the 
individual species, i.e. A + B + AB, and the overall distribution of macromolecules is 
given by the sum of the individual contributions for each species, A, B, and AB, as, 
Cr = Cm,A . exp( aJ + Cm,B . exp( as) + Cm,AB . exp( aAB) + base (Eq.3) 
According to the law of mass action, CAB equals CA *cBIKAB, in which KAB equals the 
equilibrium constant for the associating system. Thus Equation 3 shows that 
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sedimentation and chemical equilibria exist at all radial positions in the ultracentrifuge 
cell. Equation 3 may be generalized in the form of Equation 4, for species i. 
Cr =2: Cm,i· exp( aJ + base (Eq.4) 
It should be noted that this equation is applicable to any mixture of sedimenting species. 
The monomer molecular weights for vitronectin and Fab determined using Equation 1, as 
described above, will be used in Equation 4 to calculate the molecular weight of the 
complex. Data were analyzed using nonlinear least squares methods, as described by 
Brooks, et aI., 1994 using IGOR (Wavemetrics, Lake Oswego, OR). 
Crystal Screening: Vitronectin from a precipitated ammonium sulfate slurry and 
Fab thawed in an ice bucket will be dialyzed extensively against a 0.02 M Tris, pH 7.4 at 
4°C. The complex will be incubated for one hour using the molar ratios determined from 
optimization experiments. Purity of the vitronectin-Fab sample will be analyzed using 
SDS-PAGE. The vitronectin-Fab sample will be concentrated to approximately 10 
mg/ml using a .5 Ultrafree™ 30,000 MWCO centrifugal concentration device and prior 
to screening, any amorphous material present in the sample will be removed by 
centrifugation at 10,000 RPM at 4°C. 
Screening of crystallization conditions for the vitronectin-Fab complex will be 
performed using the hanging-drop vapor diffusion method using two approaches. The 
first will be the standard screening method (Jancarik, & Kim, 1991; Cudney, et aI., 1994) 
using Crystal Screen™ and Index™ kits. The second approach will employ Low Ionic 
Strength™ crystal screen from Hampton Research. The protocol has been shown to be 
an effective screen for determining the preliminary crystallization conditions of intact 
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monoclonal antibodies, monoclonal antibody fragments, and other soluble proteins 
(Harris, et al., 1995). An extremely broad range of pH 2.0 to 12.0 is sampled. At low 
ionic strength the effects of pH and temperature upon protein solubility are augmented, 
thus this screen allows one to critically evaluate the effects of solubility in crystallization. 
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Chapter Three 
EXPRESSION OF RECOMBINANT, FULL-LENGTH, NATIVE, 
MONOMERIC VITRONECTIN IN BABY HAMSTERT KIDNEY 
CELLS (BHK cells) 
Rationale: Vitronectin research is technically demanding from a laboratory 
standpoint. Preparations of native vitronectin from pooled human plasma takes 
approximately 2 weeks, and the protein yield is only between 5-30 mg. As a result, one 
vitronectin preparation generates only enough protein for a limited number of 
experiments, for crystallization studies require milligram quantities of the protein. Thus, 
the lack of an expression system for generating recombinant, full-length vitronectin has 
impeded many facets of vitronectin research, namely structural studies 
The power of site-directed mutagenesis (SDM) is demonstrated by its utility in 
nearly all facets of protein research. The ability to use this technique in the study of a 
particular protein relies on the capability to recombinantly express it. Such recombinant 
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expreSSIon becomes a significant tool for protein manipulation. With vitronectin 
crystallization in particular, SDM would allow the expression of a deglycosylated mutant 
that has not been able to be generated via standard enzyme-based chemistry. 
Additionally, vitronectin exists natively in serum in two forms, a double chain form and 
a single chain form that results from post-translational, proteolytic cleavage. Because 
crystallization is dependent upon sample homogeneity, SDM could allow the expression 
and therefore purification of a one-chain, homogenous vitronectin sample better suited 
for crystal screening. With these facts in mind, I have devoted focus into the successful 
recombinant expression of vitronectin. Success in this endeavor would not only decrease 
the laborious, low-yield process of vitronectin isolation from human serum, but it would 
also allow SDM to be employed in crystallization studies and augment the promise of my 
research. 
Successful expreSSIon of mammalian serum proteins such as factor XIII, 
transferring, and antithrombin III has been performed using the pNUT/BHK expression 
system (Fan, et al. 1993). In light of this success, this expression system will be used in 
an attempt to express full-length vitronectin. 
Experimental Procedures 
Materials: An Escherichia coli Ml190 strain housing the vitronectin gene was 
prepared by Dr. Cynthia Peterson. Oligonucleotide primers for PCR were purchased 
from Oligos Etc®. Plasmid DNA isolation was performed using a MiniPrepTM Kit from 
Promega. PCR and transformation experiments were performed using the T A Cloning 
Kit from Invitrogen®. 
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Engineering NotI Restriction Sites into the Vitronectin Gene: The plasmid from 
an Escherichia coli Ml190 strain housing the 1.7 k.b. vitronectin gene in pUC18 (fig. 4-
1) was isolated from a SO ml cell culture. Oligonucleotide primers (fig 4-2) were 
designed so as to engineer a NotI restriction (GCGGCCGC) site on the S' and 3' termini 
of the gene. The vitronectin gene was PCR amplified for 30 cycles using the NotI-tagged 
primers. The SO J.ll PCR reaction volume consisted of 1.0 J.ll pUC18-vitronectin plasmid 
template, S J.lllOX PCR buffer (60 mM Tris-HCl, pH 7.S/60 mM MgCh/SO mM NaCll1 
mg/ml bovine serum albuminl70 mM ~-mercaptoethanol/1 mM ATP /20 mM 
dithiothreitol 110 mM spermidine), .S J.ll of SOmM dNTPs (12.S mM dATPI12.S mM 
dCTP 112.S mM dGTP 112.S mM dTTP, adjusted to pH 8.0), S J.ll primer, 32.S J.ll sterile 
water, and 1.0 J.ll XTaqTM DNA polymerase (Innis, et al.,1990Z). Amplification was 
assayed using agarose gel electrophoresis with ethidium bromide under a U.V. lamp (fig. 
3-3). 
The resulting PCR product will be cloned into a pCR2.1 ™ (Invitrogen) shuttle 
vector, which will be used to transform the plasmid into competent cells. The sequence 
of the gene will be sequenced in order to verify the directionality of my insert as well as 
verify PCR integrity. The NotI-tagged vitronectin gene will be cloned into pNUT, which 
harbors an inducible, mammalian promoter, and the pNUT vector will be used to express 
vitronectin recombinantly in BHK cells. 
66 
EC00109 (2676) 
ORAII (2676) 
AATII (2622) 
SSPI (2504) 
XMNI (2299) 
ASP700 (2299) 
SCAI (2180) 
CFR101 (1780) 
GSUI (1769) 
EC031 I (1760) 
pUC18 
2686 bp 
(435) 
8(439) 
lacZ· promoter 
pMB1 ori 
Fig. 4-1: pUC18 Restriction Map. The vitronectin gene was cloned into pUC18 using the 
EcoRl restriction site. 
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AT ACG CGG CCG CCT GGC ATG GGT TGC TCT GGC TGA CCA AGA GTC ATG CAA GGG CCG CTG 
CAC TGA GGG CIT CAA CGT GGA CAA GAA GTG CCA GTG TGA CGA GeT CTG CTC TTA CTA CCA 
GAG CTG CTG CAC AGA CTA TAC GGC TGA GTG CAA GeC CCA AGT GAC TCG CGG GGA TGT GIT 
CAC TAT GeC GGA GGA TGA GTA CAC GGT CTA TGA CGA TGG CGA GGA GAA AAA CAA TGe CAC 
TGT CCA TGA ACA GGT GGG GGG CCC CTC CCT GAC CTC TGA CCT CCA GGC CCA GTC CAA AGG 
GAA TCC TGA GeA GAC ACC TGT TCT GAA ACC TGA GGA AGA GGC CCC TGe GeC TGA GGT GGG 
CGe CTC TAA GeC TGA GGG GAT AGA CTC AAG GeC TGA GAC CCT TCA TCC AGG GAG ACC TCA 
GeC CCC AGe AGA GGA GGA GeT GTG CAG TGG GAA GeC CIT CGA CGe CTT CAC CGA CCT CAA 
GAA CGG ITC CCT CIT TGe CIT CCG AGG GeA GTA CTG CTA TGA ACT GGA CGA AAA GGC AGT 
GAG GeC TGG GTA CCC CAA GeT CAT CCG AGA TGT CTG GGG CAT CGA GGG CCC CAT CGA TGe 
CGe CTT CAC CCG CAT CAA CTG TCA GGG GAA GAC CTA CCT crr CAA GGG TAA TCA GTA CTG GeG 
CIT TGA GGA TGG TGT CCT GGA CCC TGA ITA CCC CCG AAA TAT CTC TGA CGG CTT CGA TGG CAT 
CCC GGA CAA CGT GGA TGe AGe CIT GGC CCT CCC TGe CCA TAG CTA CAG TGG CCG GGA GeG 
GGT CTA CTT CTT CAA GGG GAA ACA GTA CTG GGA GTA CCA GIT CCA GeA CCA GeC CAG TCA 
GGA GGA GTG TGA AGG CAG CTC CCT GTC GGC TGT GTT TGA ACA CIT TGe CAT GAT GeA GeG 
GGA CAG CTG GGA GGA CAT CTT CGA GeT TCT CTT CTG GGG CAG AAC CTC TGe TGG TAC CAG ACA 
GeC CCA GTT CAT TAG CCG GGA CTG GeA CGG TGT GeC AGG GeA AGT GGA CGe AGe CAT GGC 
TGG CCG CAT CTA CAT CTC AGG CAT GGC ACC CCG CCC CTC CTT GAC CAA GAA ACA AAG GTT TAG 
GeA TCG CAA CCG CAA AGG CTA CCG TIC ACA ACG AGG CCA CAG CCG TGG CCG CAA CCA GAA 
CTC CCG CCG GeC ATC CCG CGe CAT GTG GeT GTC crr GTT CTC CAG TGA GGA GAG CAA CIT GGG 
AGeCAACAACTATGATGACTACAGGATGGACTGGeTTGTGeCTGeCACCTGTGAACCCAT 
CCA GAG TGT CIT CTT CTT CTC TGG AGA CAA GTA CTA CCG AGT CAA TCT TCG CAC ACG GeG AGT 
GGA CAC TGT GGA CCC TCC CTA CCC ACG CTC CAT CGe TCA GTA CTG GeT GGG CTG CCC AGe TCC 
TGG CCA TCT GTA GGA GTC AGA GeC CAC ATG GeC GGG CCC TCT GTA GeT CCC TCC TCC CAT CTC 
CIT CCC CCA GeC CAA TAA AGG TCC crr AGe GGC CGC AAA 
Figure 4-2: The 1 502 base sequence of the . The sequences highlighted in yellow 
constitute the oligonucleotide primer sequences used to mutate in the NotI restriction 
enzyme sites. Bases shown in blue are the NotI restriction sequences. The red sequence 
denotes the start codon initiating the open reading frame of the human vitronectin gene. 
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8.454 k.b. 
1.929 k.b. 
Lambda 
BstEII DNA 
Standards PCRProduct 
( 1.7 k.h. 
Figure 4-3: 1% Agarose Gel peR Product Analysis: the 1.7 k.b. vitronectin gene with 
engineered 5' and 3' NotI restriction sites 
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